HER2-positive breast cancer cell lines derived from transgenic HuHER2 mouse model

Case ID:
C13995
Disclosure Date:
2/5/2016
Description:

Unmet Need
Preclinical evaluation of therapeutic agents against metastatic breast cancer require cell lines and animal models that recapitulate clinical metastatic breast cancer.

Technology Overview
Researchers at Johns Hopkins University extracted primary mammary gland tumors, purified the epithelial breast cancer cells over a number of passages, and established 7 different HuHER-2 cell lines. These lines show all the hallmarks of highly aggressive, metastatic breast cancer and are being used to establish a left cardiac ventricle injection model of widespread HER-2/neu positive metastatic breast cancer to evaluate combination therapy with alpha-particle emitter labeled HER-2/neu reactive antibodies.
These cell lines were derived from a transgenic mouse that expresses the human HER-2/neu.  No such lines have been reported in the literature and it is likely that no other lab has developed these, they are useful for investigation related to using HER-2/neu targeting reagents. 
 
Stage of Development 
Tangible material. 

Publications

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620237/
https://www.ncbi.nlm.nih.gov/pubmed/%20%20%20%20%20%2018829490
 

Patent Information:
Inventors:
Category(s):
For Information, Contact:
Christine Joseph
cjoseph6@jhmi.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum